Archives des études
Toutes les études
Page 6 sur 45 · 1080 études
42/100
Silex Systems: A Scarce Enrichment Option Priced for Commercial Success It Has Yet to Earn
Silex Systems is not a uranium miner but a technology-commercialisation vehicle whose value rests on the SILEX laser enrichment process and a 51% stake in Global Laser Enrichment, the scarce listed proxy for rebuilding Western uranium-enrichment capacity. October 2025's independently validated TRL-6 milestone and U.S. policy support are real, yet the parent still burns negative owner earnings after roughly A$36m of annual GLE funding, and at A$4.50 the shares already trade above the A$3.70 conservative fair value. Rating Hold: genuine technical and policy progress, but the stock prices in a large amount of licensing and commercialisation success before it is earned.
47/100
56Buffett
Ningbo Orient Wires & Cables: A Real Submarine-Cable Moat Priced for Flawless Backlog Conversion
Ningbo Orient Wires & Cables is China's specialist in submarine and high-voltage transmission cable systems, having grown 2025 revenue to CNY 10.84 billion behind a CNY 18.41 billion project backlog running 1.7 times that base. Submarine and high-voltage cable revenue jumped 65.6% in 2025 to near half of sales, yet receivables and inventory are swelling just as fast and the current CNY 38.93 price already sits above the conservative buy zone. Rating Watch: a genuine niche moat already priced for flawless backlog conversion, leaving little room for timing mistakes.
42/100
49Buffett
QIAGEN: Sticky Workflow Economics With Takeover Optionality Already in the Price
QIAGEN is a molecular diagnostics and life-science tools company that monetizes an entire lab workflow, from sample prep to assays, automation and bioinformatics, selling to more than 500,000 customers across five growth pillars that target about $1.61 billion of 2026 sales. The recurring consumables model is genuinely sticky, but core organic growth still needs repair while the stock carries takeover optionality after Reuters reported KKR and strategic interest. Rating Hold: at $41.51 the shares sit inside the acceptable-hold band of $39-53, above the ideal buy zone of $30-32, so buyers are paying for both a standalone repair and a deal premium that may not arrive.
40/100
Paladin Energy: The Restart Is Working, and the Price Already Knows It
Paladin Energy is an Australian-listed uranium miner whose cash engine is the 75%-owned Langer Heinrich restart in Namibia, with Patterson Lake South in Saskatchewan as a later-dated growth option targeting first production in 2031. March-2026 quarterly production reached 1.29 million pounds with plant recovery at 92%, prompting management to raise FY2026 guidance to 4.5-4.8 million pounds, yet the December-2025 half-year still showed a US$15.1 million statutory after-tax loss and PLS carries a US$1.226 billion pre-production capital estimate. Rating Hold: at A$9.18 the stock sits inside the acceptable-hold band of A$8.0-10.8, above the ideal buy zone of A$6.0-7.0, paying roughly fair value for a successful ramp plus meaningful PLS credit.
36/100
Trina Solar: Surviving the Solar Glut While the Old Profit Engine Is Still Underwater
Trina Solar is a Chinese solar manufacturer spanning modules, storage, system solutions, and digital energy, with 2025 module shipments of 67.879 GW keeping it in the industry's second tier. 2025 revenue fell 16.61% to RMB 66.98 billion with a RMB 7.03 billion net loss and a negative PV-product gross margin, while storage revenue grew 83.3% at a 14.69% gross margin, real new businesses that are still too small to carry the group. Rating Hold: at CNY 12.18 the stock sits inside the acceptable-hold band of CNY 10.8-14.4, above the ideal buy zone of CNY 9.0-9.8.
47/100
64Buffett
Exelixis: A Real Cabozantinib Cash Machine Pricing In an Unproven Second Act
Exelixis is a commercial-stage oncology biotech whose economics still flow almost entirely through cabozantinib, sold as CABOMETYX in the U.S. and monetized abroad through royalty deals with Ipsen and Takeda. 2025 total revenue reached $2.320 billion with $782.6 million of net income and $884.3 million of operating cash flow, and the market now waits on a December 3, 2026 FDA decision for zanzalintinib in colorectal cancer, the company's attempt to build a second franchise. Rating Hold: the cabozantinib business is real and cash-generative, but at $55.75 the price already assumes a credible handoff to zanzalintinib, leaving limited margin of safety either way.
41/100
Energy Fuels: A Genuine Uranium Ramp, Priced Ahead of an Unbuilt Rare-Earth Chain
Energy Fuels operates White Mesa, the only fully licensed conventional uranium mill in the U.S., and is using that platform to move from uranium ore processing into rare-earth separation and critical-minerals feedstock through the Base, ASM, and VAC deals. 2025 revenue was just $65.9 million with an $85.6 million net loss, yet the stock trades at a $3.17 billion market cap that already prices in a mine-to-magnet chain still years from closing and commercializing. Rating Hold: the uranium ramp is real and improving, but at $12.67 the shares already bank future rare-earth and magnet success, leaving little margin of safety.
44/100
Hangzhou Tigermed: A Genuine China CRO Recovery, Priced Ahead of Clean Earnings
Hangzhou Tigermed is China's largest homegrown clinical CRO, running a domestic clinical-trial franchise alongside a fast-growing overseas and laboratory-services business that together produced RMB 6.83 billion of 2025 revenue. Bookings and backlog both re-accelerated in 2025 (net new bookings up 20.6%, backlog up 15.4%) and first-quarter 2026 operating cash flow rose 60.5%, yet adjusted attributable profit still fell 58.5% to RMB 355 million and the controlling shareholders have been under CSRC investigation over historical disclosure issues since May 2026. Rating Hold: the recovery in orders and cash flow is real, but at CNY 51.90 the A-share already prices much of that repair while clean earnings quality and governance credibility still need proof, leaving little margin of safety.
44/100
76Buffett
Eckert & Ziegler SE: A Better Business, Not Yet a Better Price
Eckert & Ziegler is a Berlin-based radioisotope specialist supplying generators, isotope products and CDMO services whose Medical segment is becoming the group's real profit engine as radiopharmaceutical oncology increasingly relies on lutetium-177 and actinium-225. 2025 revenue reached €312.0 million with Medical gross margin climbing to 49% and net financial position ending the year at €115.2 million, but 2026 guidance implies only about 3% revenue and adjusted-EBIT growth. Rating Hold: at €14.43 the stock already sits close to its conservative fair-value zone of €11.0–11.8, leaving minimal margin of safety for new buyers.
40/100
53Buffett
Sumitomo Electric Industries: The Transition Is Real, But So Is the Price
Sumitomo Electric is a diversified Japanese cable-and-components maker whose profit mix is shifting away from its low-margin automotive wire-harness base toward higher-margin AI-driven optical interconnects and high-voltage power cables. FY2025 sales reached ¥5.11 trillion with operating profit up 30.4% to ¥418.2 billion, but a meaningful share of the profit surge came from a one-off ¥79.2 billion asset-sale gain, and management's own FY2027 guidance implies only modest further growth. Rating Hold: at ¥2,458.5 the stock already prices much of the transition, leaving no margin of safety at the current level.
46/100
Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act
Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.
33/100
Uranium Energy Corp: Scarce U.S. Uranium Assets, Priced Ahead of the Proof
Uranium Energy Corp is a U.S. in-situ-recovery uranium miner running the country's only two active ISR production hubs, in Wyoming and South Texas, while building toward a domestic conversion business through its UR&C subsidiary. The balance sheet is genuinely strong, with $489.9 million in cash plus restricted cash and no debt as of April 2026, but five-year operating cash flow totaled roughly negative $192.8 million, 2025 revenue of $66.8 million still came mainly from selling purchased inventory rather than mined output, and shares outstanding rose from 378.5 million to 493.3 million since 2023. Rating Avoid: the licensed U.S. permits and policy tailwinds are real, but at $10.07 the stock already sits above even the report's optimistic per-share fair value of $9.02, leaving no margin of safety.
45/100
55Buffett
Vicor: A Real Power-Delivery Specialist, Already Priced For AI's Promise
Vicor is a specialist power-conversion supplier whose Factorized Power Architecture and modular DC-DC building blocks target the 'last-inch' power-delivery bottleneck between AI processors and the board, monetizing both product sales and a fast-growing patent-royalty stream. Full-year 2025 revenue rose 13.5% to $407.7 million with gross margin reaching 57.3% as royalty revenue grew from $15.9 million in 2023 to $57.4 million in 2025, and first-quarter 2026 backlog jumped 75% year over year to $301 million, yet the company still has not disclosed the hyperscaler customers the market assumes it serves. Rating Watch: the technical edge and momentum are real, but at a trailing P/E above 84x and zero margin of safety against the conservative scenario, the stock already prices years of unproven customer breadth.
50/100
BeOne Medicines: A Real Oncology Winner, Already Priced For More
BeOne Medicines, formerly BeiGene, is a global oncology biopharma whose economics now turn on one drug, BRUKINSA, the BTK inhibitor that outsold AstraZeneca's Calquence and AbbVie's Imbruvica in 2025 with $3.93 billion of revenue as the company crossed into sustained GAAP profitability. Full-year 2025 revenue reached $5.34 billion with $1.13 billion of operating cash flow, and first-quarter 2026 extended the trend with an 89% gross margin and raised full-year guidance, even as BRUKINSA still supplies roughly three-quarters of product revenue. Rating Hold: commercial execution and BTK leadership are real and durable, but at $303.96 the stock already prices continued BRUKINSA strength and a successful platform broadening that remains unproven, leaving no meaningful margin of safety.
37/100
42Buffett
Changzhou Juhe: Real Moat, Unproven Second Curve
Changzhou Juhe is a Shanghai STAR-listed producer of photovoltaic conductive paste whose economics turn on processing gross profit rather than headline, silver-inflated revenue. Full-year 2025 revenue reached CNY 14.59 billion but net profit barely moved to CNY 419.7 million, while operating cash flow stayed deeply negative at CNY 3.07 billion even as first-quarter 2026 gross margin jumped to a record 10.58% on stronger overseas mix. Rating Hold: execution and customer embedding are real, but at CNY 100.05 the stock already prices a margin recovery and a de-silvering transition that remain unproven, leaving no meaningful margin of safety.
43/100
Hanwei Technology: Good Technology, Bad Price
Hanwei Technology is a Shenzhen-listed industrial sensing company whose revenue now centers on smart instruments and integrated monitoring solutions rather than the stand-alone gas sensors it is still best known for, with a pending Hong Kong H-share listing adding a live capital-markets catalyst. Full-year 2025 revenue recovered 8.35% and attributable profit jumped 107.1% to CNY 158.8 million, but non-recurring-excluded profit was only CNY 38.6 million and the stock already trades around 75 times trailing earnings and 4.3 times book, well above its own CNY 16-22 ideal-buy range. Rating Avoid: the sensing technology and portfolio cleanup are real, but the price already assumes a cleaner, more proven earnings run rate than five years of weak cash conversion have delivered.
38/100
Eastman Chemical: A Cyclical Repair Story Already Priced for Stabilization
Eastman Chemical is a US specialty materials producer that has spent three decades shifting from a commodity chemical maker into a four-segment franchise, Advanced Materials, Additives & Functional Products, Chemical Intermediates, and Fibers, anchored by differentiated plastics, additives, and the Kingsport molecular-recycling platform. First-quarter 2026 revenue fell to $2.177 billion and adjusted EPS to $1.09 year over year, even as specialty volume rose more than 10 percent sequentially and 2026 capital spending is guided down to about $400 million from $546 million, improving cash conversion without requiring a demand recovery. Rating Hold: the portfolio's quality has genuinely improved and the shares yield near 5 percent, but auto, construction, and Chemical Intermediates weakness mean the current price already reflects the stabilization story, leaving little margin of safety.
44/100
ACWA Power: A Compelling National Champion Wrapped in an Undisciplined Valuation
ACWA Power is a Saudi project-finance platform, 44%-owned by sovereign wealth fund PIF, that develops and operates contracted power, desalination, and green-hydrogen assets; assets under management reached SAR 455 billion in the first quarter of 2026, even as adjusted net profit fell 34.3% year over year. The stock trades around 82x trailing earnings with 5.2x parent leverage, and even the report's optimistic SAR 170 valuation ceiling sits below the current SAR 192 price. Rating Watch: the strategic position is real, but the price has already paid for growth the business has not yet delivered.
34/100
AXT: A Real Indium Phosphide Bottleneck, Priced Well Ahead of the Business
AXT is a U.S.-listed, China-manufactured supplier of compound semiconductor substrates whose economics now hinge on indium phosphide demand from the AI optical build-out and on Chinese export-permit timing. The stock rose roughly 40-fold from its August 2025 low to today's $57.21 close on real InP backlog growth and two large equity raises, yet still trades around 35-40 times trailing sales while remaining loss-making and fully dependent on Beijing's permit cadence. Rating Avoid: the bottleneck is real, but the price already assumes a cleaner, faster payoff than the business has actually earned.
39/100
Solstice Advanced Materials: A Real Standalone Business, Not Enough Margin of Safety for the Deal
Solstice Advanced Materials is a recent Honeywell spin-off whose cash engine is refrigerants and applied solutions, now also building electronics materials and uranium-conversion businesses, and its first standalone year held up better than headline GAAP profit suggested. On July 6, 2026 the company agreed to acquire Element Solutions for about $14.5 billion in cash and stock, a deal that lifts net leverage from roughly 1.5x to 3.5x and dilutes existing holders to about 56% of the combined company, sending the stock from $82.80 down to $61.30. Rating Hold: the standalone business is genuinely solid, but today's price still does not offer enough margin of safety for both execution risk and deal risk at once.
43/100
Fervo Energy: The Geothermal Buildout Is Real, the Margin of Safety Is Not
Fervo Energy is a newly public enhanced-geothermal developer building utility-scale, contracted 24/7 power plants under its Cape Station program, still pre-commercial today with barely any revenue. The company has signed 658 MW of power purchase agreements worth about $7.2 billion in backlog and closed a $421.4 million non-recourse project-finance package, yet Q1 2026 revenue was just $61,000 against a $31.8 million net loss, and Phase II alone still needs roughly $2.2 billion more through 2028. Rating Hold: the commercial and financing progress is real, but at $27.13 the stock already sits above the conservative fair-value range, leaving essentially no margin of safety until Cape Station proves itself in operation.
37/100
China XD Electric: A Real UHV Upcycle, Priced Like It's Already Proven
China XD Electric is a central-SOE-controlled maker of UHV transmission and substation equipment, spanning switchgear, transformers and power-electronics devices, whose 2025 revenue grew 7.1% to RMB 23.76 billion and attributable net profit grew 20.5% to RMB 1.27 billion as gross margin improved 1.86 percentage points to 22.57% on a richer transformer mix. Rating Hold: order flow and margin gains are real and the balance sheet is safe, but at RMB 13.42 the stock already trades near 54 times trailing earnings on a 2025 ROE of just 5.64%, pricing in continued execution well ahead of the report's own ideal buy zone of RMB 8.0 to 9.0.
44/100
63Buffett
Sieyuan Electric: A Premium-Priced Export Compounder With Zero Margin of Safety
Sieyuan Electric is a founder-controlled Chinese power-equipment exporter whose overseas revenue reached 26.94% of 2025 sales, up 85.84% year on year, helping drive 2025 revenue growth of 39.3% to RMB 21.54 billion and net-profit growth of 53.7% to RMB 3.15 billion, even as operating cash flow of RMB 2.23 billion trailed profit and a Toshiba-related stake cut from 90% to 70% now leaks more earnings to minority holders. Rating Watch: business quality is real, but at RMB 151.73 the stock trades near 37.6 times trailing earnings, well above domestic peers Xuji, Pinggao and NARI, pricing in years of clean execution with zero margin of safety against the report's RMB 95 conservative fair value, with the ideal buy zone at RMB 78 to 88.
31/100
XJ Electric: A High-Margin HVDC Niche, But No Margin of Safety at Today's Price
XJ Electric is a state-controlled Chinese grid-equipment maker where a small HVDC converter-valve and DC control-and-protection segment, just 6.79% of 2025 revenue, delivered a 32.71% gross margin and lifted group profitability even as total 2025 revenue fell 12.27% to RMB 14.99 billion and Q1 2026 attributable profit dropped 46.50% on delivery-timing swings. Rating Hold: operating cash flow has consistently exceeded net profit and the HVDC option is real, but at RMB 20.20 the stock already sits in the acceptable-hold band with zero margin of safety against project-timing and customer-concentration risk, with the ideal buy zone at RMB 12.5 to 14.0.